Researchers announced today that the first randomized regulated trial of entire plant cannabis as a treatment for posttraumatic tension condition (PTSD) symptoms has almost finished enrollment, with just 7 areas remaining for U.S. military veterans to volunteer. So far, 69 out of 76 veterans have actually gotten treatment in the research study. Sponsored by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS), the study is evaluating the safety and efficiency of smoked cannabis to treat symptoms of PTSD in 76 U.S. veterans.
” We are elated to lastly be in the house stretch of this regulated trial that began its journey over Ten Years earlier,” stated researcher Dr. Sue Sisley.” We just have seven spots offered for veterans to still be enrolled in the research study, but they must be evaluated before the end of October in order to be eligible. This is their last opportunity to participate in the first research study of cannabis in veterans with PTSD being performed under FDA assistance.”
The results will supply medical professionals, clients, scientists, and regulators with crucial understanding relating to whether cannabis benefits people with PTSD, whether adverse consequences take place, and the impact of the chemical structure of marijuana, specifically ∆ -9- tetrahydrocannabinol (THC) and cannabidiol (CBD), on scientific results. The information from the trial will be finalized in early 2019, after which the results will be gotten ready for publication.
The research study is funded by a $2.156 million grant to MAPS from the Colorado Department of Public Health and Environment, and carried out with approval and oversight from the United States Fda (FDA), Drug Enforcement Administration (DEA), and the National Institute on Drug Abuse (NIDA).
” We are working to complete this trial for the advantage of medical marijuana patients in Colorado, and all throughout the United States,” stated MAPS founder and executive director Rick Doblin, Ph.D. “FDA approval of entire plant medical marijuana would indicate that patients might have their medical cannabis covered by insurance, although that possibility is currently obstructed by the Department of Justice-enforced NIDA monopoly on cannabis for research.”
Participants should be adult military veterans with chronic, treatment-resistant PTSD. Study volunteers will finish 17 outpatient study visits over 12 weeks. Eligibility is figured out by medical assessment. Individuals need to have the ability to visit the research study site at the Scottsdale Research Institute in Phoenix, Arizona, for all arranged visits.